Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05165433 · ClinicalTrials.gov registry record · Phase 1
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
A Phase 1 study of Metastatic Cancer and Epithelial Tumor, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 7
- Study locations
NCT05165433 is a Phase 1 study of Metastatic Cancer and Epithelial Tumor that has completed, run by Akamis Bio. The registered enrollment target is 14 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05165433, a Phase 1 study of Metastatic Cancer and Epithelial Tumor, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
Conditions Studied
Interventions
- BIOLOGICAL NG-350A plus Pembrolizumab
Study Locations (7)
California
- Providence Medical Foundation - Santa Monica
- UCLA - Santa Monica
Florida
- Moffitt-Advent Health Clinical Research Unit - Celebration
Pennsylvania
- Perelman Center of Advanced Medicine - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Lancashire
- The Clatterbridge Cancer Centre NHS Foundation Trust - Liverpool
Oxfordshire
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust - Oxford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05165433
The ClinicalTrials.gov registry entry for NCT05165433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Akamis Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which NG-350A plus Pembrolizumab is the first listed.
NCT05165433 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05165433 about?
NCT05165433 is a clinical study titled "Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)". This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
What is the current status of trial NCT05165433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-04-13. Estimated completion is 2025-09-26.
What conditions does trial NCT05165433 study?
This clinical trial studies the following conditions: Metastatic Cancer, Epithelial Tumor.
What interventions are being tested in trial NCT05165433?
The interventions under investigation include: NG-350A plus Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05165433?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05165433 being conducted?
This trial has 7 study locations across California, Florida, Pennsylvania, Texas, Lancashire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.